$692.9M in CY2024 Part D spend522K claims · 154K beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Ubrogepant used for?
Ubrogepant is a Calcitonin Gene-related Peptide Receptor Antagonist medication tracked in Medicare Part D.
Is there a generic for Ubrogepant?
No. Ubrogepant is brand-only with no generic equivalents currently in market.
How much does my plan pay for Ubrogepant?
Across 329 Part D plans, Ubrogepant averages $109.15/unit (NADAC). Lowest available: $109.08/unit. Highest in distribution: $109.19/unit.
Is Ubrogepant on the FDA shortage list?
No. Ubrogepant is not currently on the FDA Drug Shortage Database.
8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.